Rapport Therapeutics, Inc. Common Stock (RAPP) Financial Ratios
4 years of historical data (2022–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
3.87
↑+87% vs avg
5yr avg: 2.07
30Y Low1.2·High2.9
ROE
↑
-28.2%
↓+39% vs avg
5yr avg: -46.3%
30Y Low-56%·High-28%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RAPP Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Rapport Therapeutics, Inc. Common Stock currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Market Cap | $1.5B | $1.4B | $368M | — | — |
| Enterprise Value | $1.4B | $1.4B | $313M | — | — |
| P/E Ratio → | -13.96 | — | — | — | — |
| P/S Ratio | — | — | — | — | — |
| P/B Ratio | 3.87 | 2.94 | 1.20 | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RAPP EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
RAPP Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -28.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| ROE | -28.2% | -28.2% | -56.0% | — | -54.6% |
| ROA | -26.9% | -26.9% | -33.3% | -37.2% | -33.7% |
| ROIC | -27.1% | -27.1% | -79.6% | — | — |
| ROCE | -31.3% | -31.3% | -36.7% | -41.0% | -34.6% |
RAPP Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $53M exceeds total debt of $11M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.00 | — | 0.53 |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | -0.08 | -0.18 | — | -1.06 |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -36.38 |
Net cash position: cash ($53M) exceeds total debt ($11M)
RAPP Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Rapport Therapeutics, Inc. Common Stock's current ratio of 26.17x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 17.14x to 26.17x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Current Ratio | 26.17 | 26.17 | 35.34 | 17.14 | 18.80 |
| Quick Ratio | 26.17 | 26.17 | 35.34 | 17.14 | 18.80 |
| Cash Ratio | 25.75 | 25.75 | 34.82 | 16.75 | 18.74 |
| Asset Turnover | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
RAPP Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Rapport Therapeutics, Inc. Common Stock does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $47M | $21M | $18M | $20M |
Peer Comparison
Compare RAPP with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RAPPYou | $1B | -14.0 | — | — | — | — | -28.2% | -27.1% | — |
 PTCT | $5B | 8.3 | 5.4 | 7.6 | 95.9% | 49.5% | — | — | 0.5 |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 LGND | $4B | -956.0 | 322.1 | 53.4 | 93.4% | -13.5% | -0.5% | -2.3% | 0.6 |
 ARVN | $652M | -8.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 AXSM | $11B | -59.8 | — | — | 92.6% | -26.5% | -252.1% | -1906.7% | — |
 SRRK | $5B | -14.1 | — | — | — | — | -123.1% | -201.2% | — |
 LLY | $921B | 42.5 | 30.6 | 102.7 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 4 years · Updated daily
See RAPP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RAPP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RAPP vs PTCT
Side-by-side business, growth, and profitability comparison vs PTC Therapeutics, Inc..
Start ComparisonRAPP — Frequently Asked Questions
Quick answers to the most common questions about buying RAPP stock.
What is Rapport Therapeutics, Inc. Common Stock's P/E ratio?
Rapport Therapeutics, Inc. Common Stock's current P/E ratio is -14.0x. This places it at the 50th percentile of its historical range.
What is Rapport Therapeutics, Inc. Common Stock's ROE?
Rapport Therapeutics, Inc. Common Stock's return on equity (ROE) is -28.2%. The historical average is -46.3%.
Is RAPP stock overvalued?
Based on historical data, Rapport Therapeutics, Inc. Common Stock is trading at a P/E of -14.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.